Keeping pace with the European market access environment

The past few years have seen considerable reform to how medicines are valued and assessed, yet arguably the most significant change to European market access is still yet to come.

As we wait for the European Joint Clinical Assessment regulation to come into force, Lightning Health’s Joint Managing Directors, Andrew Satherley and James Whitehouse explore the role that pharmaceutical innovation has had on European assessment to date, and how future patient access can be accelerated if real-world insights are routinely used to inform market access strategies.

View the video here